

WHO Prequalification Programme
WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

[MA169 trade name]*

Amodiaquine (as hydrochloride) 150 mg dispersible tablets +
Pyrimethamine/Sulfadoxine 25 mg/500 mg dispersible tablets

[MA169 trade name], manufactured at Universal Corporation Limited, Kikuyu, Kenya, was included in the WHO list of prequalified medicinal products for malaria prevention on 30 July 2023.

[MA169 trade name] is indicated for malaria prevention during the malaria season (seasonal malaria chemoprevention, SMC) in children. Detailed information on the use of this product is described in the summary of product characteristics (SmPC), which can be found in this WHOPAR.

The active pharmaceutical ingredients of [MA169 trade name] are amodiaquine (as hydrochloride), pyrimethamine and sulfadoxine.

The efficacy and safety of amodiaquine (as hydrochloride), pyrimethamine and sulfadoxine are well established based on extensive clinical experience in the malaria prevention.

For details on the uses of this product and for side effects and warnings, see Part 4 of this WHOPAR (summary of product characteristics).

On the basis of data submitted and public information on the use of amodiaquine (as hydrochloride), pyrimethamine and sulfadoxine in malaria prevention, the team of assessors advised that [MA169 trade name] is of acceptable quality, efficacy and safety to allow inclusion of [MA169 trade name] in the list of prequalified medicinal products.

Summary of prequalification status for [MA169 trade name]:

The table shows the status of relevant completed activities, including the dates of WHO internal quality assurance.

* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

Initial acceptance	Date	Outcome
Status on PQ list	30 July 2023	listed
Pharmaceutical quality	20 January 2023	MR
Bioequivalence	24 January 2023	MR
Safety, efficacy	NA	NA
GMP (re-)inspection		
API	22 June 2021	MR*
APIs	24 June 2022	MR
APIs	28 June 2022	MR
FPP	17 March 2023	MR
GCP/GLP (re-)inspection	27 July 2020	MR*
GCP/GLP (re-)inspection	27 May 2022	MR
API: active pharmaceutical ingredient FPP: finished pharmaceutical product GCP: good clinical practice [quality standard] GLP: good laboratory practice [quality standard] GMP: good manufacturing practice [quality standard] MR: meets requirements MR*: desk review (based on recent inspection reports) NA: not applicable, not available PQ: prequalification		

The table represents the status of relevant completed activities only.